Anthra Pharmaceuticals announces development agreement with Schering AG, Germany.PRINCETON, N.J.--(BUSINESS WIRE)--Sept. 25, 1995--Anthra Pharmaceuticals Inc. announced today the signing of worldwide research and development, stock purchase, and license agreements between Anthra and Schering AG, Germany and its U.S. affiliate, Schering Berlin Venture Corp. The agreements involve Anthra's lead product, AD 32, which is a novel, highly-lipophilic and well-tolerated anthracycline anthracycline /an·thra·cy·cline/ (-si´klen) a class of antineoplastic antibiotics produced by Streptomyces peucetius and S. coeruleorubidus, including daunomycin and doxorubicin. in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical studies in the U.S. for the treatment of a range of urologic and oncologic on·col·o·gy n. The branch of medicine that deals with tumors, including study of their development, diagnosis, treatment, and prevention. [Greek onkos, mass, tumor; see nek- cancers including superficial superficial /su·per·fi·cial/ (-fish´al) pertaining to or situated near the surface. su·per·fi·cial adj. 1. Of, affecting, or being on or near the surface. 2. bladder cancer bladder cancer Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor. and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . Under the license and research and development agreements, Schering AG, Germany will provide a majority of funding for the development of a variety of urologic and oncologic indications involving AD 32. Schering AG, Germany will also make payments on the achievement of certain development milestones and will pay royalties on worldwide sales of AD 32. Schering AG, Germany will retain exclusive, worldwide marketing rights on AD 32. Commenting on the various agreements with Schering AG, Germany, Michael C. Walker, president of Anthra Pharmaceuticals, Inc. said, "We are very pleased with the prospects of the cooperation with Schering AG, Germany. On the one hand, it helps us achieve our primary goal of developing and commercializing AD 32 in a manner that fully recognizes the potential of the product. In addition, the agreement provides Anthra with the flexibility to focus our attention on the development of other products which are complementary to AD 32 and build upon the experience we have gained thus far." Anthra Pharmaceuticals, Inc. is a development stage pharmaceutical company with a focus in products for the treatment of a variety of urologic diseases and cancer. CONTACT: Anthra Pharmaceuticals Inc., Princeton Michael C. Walker, 609/924-2680 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion